loading...| Preferred Name | Alefacept | |
| Synonyms |
|
|
| Definitions |
A recombinant dimeric fusion protein consisting of the extracellular CD2-binding domain of the human leukocyte function-associated antigen 3 (LFA-3; CD58) linked to the Fc portion of human immunoglobulin G1 (IgG1) with potential immunosuppressive activity. Alefacept binds to the CD2 receptor expressed on the majority of T lymphocytes, blocking the binding of endogenous LFA-3, located on antigen-presenting cells (APCs), to the CD2 receptor; the activation and proliferation of T lymphocytes in response to LFA-3 binding is thus inhibited. In addition, binding of the IgG1 moiety of this agent to the Fc gamma receptor on the surface of natural killer (NK)cells may bridge NK cells and target T lymphocytes, initiating NK cell-mediated apoptosis of T lymphocytes. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C65220 |
|
| ALT_DEFINITION |
A drug that is used to treat certain skin conditions and is being studied in the treatment of cutaneous (skin-related) T-cell cancer and T-cell non-Hodgkin lymphoma. Alefacept is made by combining part of an antibody with a protein that blocks the growth some types of T cells. It is a type of fusion protein and a type of immunosuppressant. |
|
| CAS_Registry |
222535-22-0 |
|
| code |
C65220 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
A recombinant dimeric fusion protein consisting of the extracellular CD2-binding domain of the human leukocyte function-associated antigen 3 (LFA-3; CD58) linked to the Fc portion of human immunoglobulin G1 (IgG1) with potential immunosuppressive activity. Alefacept binds to the CD2 receptor expressed on the majority of T lymphocytes, blocking the binding of endogenous LFA-3, located on antigen-presenting cells (APCs), to the CD2 receptor; the activation and proliferation of T lymphocytes in response to LFA-3 binding is thus inhibited. In addition, binding of the IgG1 moiety of this agent to the Fc gamma receptor on the surface of natural killer (NK)cells may bridge NK cells and target T lymphocytes, initiating NK cell-mediated apoptosis of T lymphocytes. |
|
| Display_Name |
Alefacept |
|
| FDA_UNII_Code |
ELK3V90G6C |
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Alefacept |
|
| Legacy Concept Name |
Alefacept |
|
| Maps_To |
Alefacept |
|
| NCI_Drug_Dictionary_ID |
531798 |
|
| PDQ_Closed_Trial_Search_ID |
531798 |
|
| PDQ_Open_Trial_Search_ID |
531798 |
|
| Preferred_Name |
Alefacept |
|
| prefixIRI |
NCIT:C65220 |
|
| prefLabel |
Alefacept |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0962603 |
|
| subClassOf |